# A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers

> **NCT03380780** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 16 (actual)

## Conditions studied

- Healthy Volunteers
- Hemophilia A

## Interventions

- **DRUG:** Emicizumab

## Key facts

- **NCT ID:** NCT03380780
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-12
- **Primary completion:** 2018-09-18
- **Final completion:** 2018-09-18
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03380780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03380780, "A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03380780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*